| Q33981905 | Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities |
| Q48095090 | Assessing the antifungal activity of a new oral lipid-based amphotericin B formulation following administration to rats infected with Aspergillus fumigatus |
| Q42925124 | Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations |
| Q43557223 | Determination of amphotericin B in human plasma using solid-phase extraction and high-performance liquid chromatography |
| Q71221688 | Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin |
| Q74061558 | Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine |
| Q61853456 | Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: In vitro studies in normolipidemic and dyslipidemic human plasmas |
| Q43793141 | Differences in the method by which plasma is separated from whole blood influences amphotericin B plasma recovery and distribution following amphotericin B lipid complex incubation within whole blood |
| Q41378026 | Diversity of lipid-based polyene formulations and their behavior in biological systems |
| Q40410546 | Effect of heat-treated amphotericin B on renal and fungal cytotoxicity |
| Q72114036 | Effect of intralipid infusion on serum high- and low-density lipoprotein cholesterol, lecithin: Cholesterol acyltransferase, and lipoprotein lipase in tumor-bearing rats |
| Q39913211 | Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats |
| Q88670032 | Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis |
| Q39782548 | Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis. |
| Q33982523 | Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits |
| Q45117911 | Heat-treated Fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus |
| Q28261086 | Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery |
| Q39472074 | Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels |
| Q35136556 | Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients |
| Q33703093 | Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies |
| Q37428678 | Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children |
| Q45111977 | Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. |
| Q41741552 | Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs |
| Q35088663 | Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A. |
| Q33983629 | Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study |
| Q37544911 | Tissue penetration of antifungal agents. |